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Abbreviation Full term or phrase 
KS Kaposi sarcoma 
HIV Human immunodeficiency virus 
IQR Interquartile range 
CI Confidence interval  
HHV-8 Human herpesvirus 8 
ART Antiretroviral therapy 
AIDS Acquired immune deficiency syndrome  
RCT Randomized control trial  
QECH Queen Elizabeth Central Hospital 
VBE Vincristine, Bleomycin, Etoposide  
V Vincristine 
VB Vincristine, Bleomycin 
E Etoposide  
TB Tuberculosis 
LTFU Loss to follow up 
HR Hazard ratio 
CD34 Cluster of differentiation 34 
IRIS Immune reconstitution inflammatory 
syndrome 
WCC White cell count  
PCV Packed cell volume 
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3  
Abstract 42 
 43 
Background. Kaposi sarcoma (KS) is the most common paediatric cancer in HIV-endemic 44 
countries of sub-Saharan Africa but there is little research on management and outcomes. 45 
Methods.  Children with KS at Queen Elizabeth Central Hospital, Blantyre, Malawi treated between 46 
August 2012 and March 2015 with six courses of vincristine, bleomycin and etoposide combination 47 
chemotherapy including antiretroviral therapy, if HIV-infected, were studied and outcomes 48 
compared with previously reported results. 49 
Findings. Fifty-six children were included, 38 (68%) were male; 48 (86%) were HIV-positive of 50 
whom 36 (77%) were on antiretroviral therapy at diagnosis. Median age at diagnosis was 8 years 51 
(IQR 3-12) and median follow-up was 16.9 months (IQR 3.4-36.4). Quality of life improved in 45 52 
(80%) children; the median Lansky Score increased from 80% pre-treatment to 100% post-53 
treatment. Eighteen (32%) children had complete response to treatment. At 12 months overall 54 
survival was 71% (95% CI 56-82) and event-free survival (event = death, loss to follow-up or 55 
relapse) was 50% (95% CI 36-63). At one-year the risk of loss to follow-up was 13.4%. 56 
In a previous, same-site randomized controlled study of vincristine monotherapy, vincristine and 57 
bleomycin or oral etoposide, oral etoposide monotherapy had the best outcome with survival at 12 58 
month of 66% (95% CI 46-80) and event-free survival of 52% (95% CI 33-68); however, loss to 59 
follow-up was not reported. 60 
Conclusion. Overall survival, event-free survival, and quality of life appear to have improved with 61 
this three-agent combination chemotherapy; however larger, randomized studies are needed to 62 
determine optimal management. 63 
 64 
 65 
 66 
 67 
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Introduction 68 
 69 
Kaposi sarcoma (KS) is an aggressive, multifocal disease arising from vascular and lymphatic 70 
endothelial cells involving the skin and visceral organs. It is the second most frequently diagnosed 71 
HIV-related malignancy worldwide and the second most common paediatric tumour in sub-Saharan 72 
Africa where HIV and human herpesvirus 8 (HHV-8) are endemic.1 Neither HIV nor widespread 73 
KS is curable and treatment is aimed at disease reduction and improved quality of life. 74 
 75 
Antiretroviral therapy (ART) is the first line treatment for AIDS-related KS. ART alone may cause 76 
long-term regression of lesions and of localized lymphadenopathy. Systemic chemotherapy is added 77 
for patients with extensive skin involvement and disseminated or systemic disease.2,3 Adult 78 
guidelines recommend first-line usage of liposomal doxorubicin, an expensive drug not readily 79 
available in low-income countries.4-6 Paediatric data supporting its first line use are not available. 80 
Evidence in adults is unclear as to whether alternative regimens are inferior to liposomal 81 
doxorubicin.5 82 
 83 
There are no agreed paediatric KS staging criteria or treatment regimens. The AIDS Clinical Trials 84 
Group staging system that classifies tumor (T), immune status (I), and systemic illness (S) was not 85 
designed for paediatric KS and does not correlate well with outcomes in this population.7 There is a 86 
new proposed risk stratification system based on clinical characteristics of paediatric KS, and that 87 
may identify high-risk patients and guide treatment to improve overall outcomes.8 Consensus 88 
guidelines recommend considering several different treatment regimens.9 A Cochrane review of 89 
four African studies10-13 looked at four different chemotherapy regimens: single-agent vincristine, 90 
single-agent paclitaxel, bleomycin/vincristine or doxorubicin/bleomycin/vincristine. They 91 
concluded that in HIV-infected children ART and chemotherapy together increase the likelihood of 92 
KS remission and reduce the risk of death. It is unclear as to which chemotherapeutic regimen is 93 
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most effective.  94 
A study in Zimbabwean adults with KS showed that oral etoposide gave better quality of life with 95 
better psychological outcomes, less social disruption and fewer side-effects than supportive care 96 
alone, radiotherapy or a 3-drug combination of actinomycin-D, vincristine and bleomycin.14 A 97 
randomized control trial (RCT) in Malawian children comparing vincristine alone, vincristine with 98 
bleomycin and single agent oral etoposide, concluded that survival at one year was better in the oral 99 
etoposide and the vincristine/bleomycin groups, compared to vincristine alone. (Survival:deaths for 100 
etoposide, n=21:15 (66% [95% CI 46-80%]); vincristine/bleomycin, n=22:12 (57% [95% CI 36-101 
73%]); vincristine, n=22:17 (45% [95% CI 26-63%]); p=0.045 at 12 months of follow-up.15 During 102 
that study clinicians had the impression that etoposide (an anti-angiogenic drug that was given 103 
orally) took several weeks to be effective, whereas the vincristine/bleomycin combination worked 104 
more quickly. In an attempt to improve survival Malawian children with KS at the Queen Elizabeth 105 
Central Hospital (QECH) in Blantyre were treated with a three-drug chemotherapy regimen of 106 
vincristine, bleomycin and etoposide (VBE).  Thalidomide was given to some children who had 107 
treatment failure despite several courses of therapy. 108 
 109 
Methods 110 
 111 
Site 112 
The QECH is a 1,200 bedded government, tertiary hospital in Blantyre, Malawi. It is the teaching 113 
hospital for the medical school and receives referrals for the southern half of the country. The 114 
paediatric department admits 28,000 children annually and over 80,000 attend the emergency 115 
department and outpatients. The children’s oncology unit has 23 beds and admits 300 patients 116 
annually. Children with KS are treated as outpatients unless they are systemically unwell. 117 
 118 
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Patient data 119 
Data were collected on all children (<16 years) treated for KS with VBE between August 2012 and 120 
March 2015. Data included age at presentation, sex, HIV status; location, duration and number of 121 
KS cutaneous lesions, lymphadenopathy, oral cavity involvement and presence of pleural effusions, 122 
oedema, length of time on ART before the diagnosis of KS, and previous TB treatment. Baseline 123 
bloods included haematocrit (PCV), white cell count (WCC), platelets; CD4 cell count and 124 
percentage if on ARTs for over a year; weight, sentinel node size and Lansky scores before and 125 
after treatment; chemotherapy treatment, response and outcomes.  126 
 127 
KS was diagnosed clinically, with biopsy confirmation if the diagnosis was in doubt. Biopsy 128 
confirmation was required in 6 cases.  HIV infection was confirmed using two rapid tests and 129 
eligibility for ART followed national guidelines.16,17 Quality of life was assessed using the Lansky 130 
score.18 The chemotherapy regimen consisted of six courses of intravenous vincristine (1·5 mg/m2 131 
Day 1), bleomycin (15 IU/m2  Day 1) and oral etoposide (100mg/m2 Days 1-3). The second course 132 
was given after one week and further courses were fortnightly.  133 
 134 
Follow up 135 
Children were reviewed one month after completing chemotherapy and six monthly thereafter. 136 
Treatment response was assessed by measurement of sentinel KS lesions before and after treatment. 137 
Complete response was defined as no clinical evidence of KS; partial response as a decrease of 138 
>50% in lesion size; stable disease as <50% reduction and poor response was no response or 139 
deterioration in the size of the KS lesions. Relapse was defined as apparent complete recovery 140 
followed by a return of the disease. Deaths on treatment were recorded. Patients who did not 141 
complete treatment, failed to attend scheduled clinic visits or could not be traced were classified as 142 
defaulters after actively attempting to contact them. The time to progression of the disease was 143 
noted. 144 
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 145 
Data analysis 146 
Stata version 12.1 (STATA Inc., College Station, TX) was used for analyses. Descriptive analysis 147 
included summary statistics of demographic and clinical features. Chi-squared tests were used to 148 
calculate p-values for categorical variables and Wilcoxon rank-sum tests for continuous variables. 149 
Survival-time and competing risk analyses were used for survival statistics and for Kaplan-Meier 150 
plots. Logistic and cox regression were used for univariate and multivariate analysis to calculate 151 
hazard ratios and 95% confidence intervals. Multivariate regression analysis was performed in a 152 
forwards stepwise fashion including a priori variables, or those statistically significant at the 0·10 153 
level in univariate analysis, in the model. We conducted three outcome analyses; 1) Survival: only 154 
death was considered as an outcome - defaulters (abandonment) were censored at last follow-up 155 
appointment date, 2) Retention: death and default were included together as an event (attrition) 3) 156 
Event-free survival: death, default and relapse were combined as an event. 157 
 158 
Comparative raw data from the previous randomized controlled study of treatments with vincristine 159 
monotherapy or oral etoposide or combined vincristine and bleomycin were re-analysed in the same 160 
manner for comparison with our data, and with additional follow-up data compared with that 161 
presented in the previous publication. 162 
 163 
As this was an audit of departmentally approved standard treatment no formal ethical approval was 164 
required. 165 
 166 
 167 
Results 168 
 169 
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Fifty-six children of whom 38 (68%) were males were enrolled. Median age at diagnosis was 8 170 
years (IQR 3-12). Median weight for age at enrollment was -2·29 (IQR -2·64 - -0·17); but is an 171 
unreliable measure of nutrition as many children had tumour related lymphoedema, or missing data 172 
(see Table 1). Forty-eight children (86%) had HIV infection of whom 36 (77%) had received ART 173 
for a median duration of 10 months (IQR 1·6-23·5). The 12 (23%) ART naïve children commenced 174 
ART as soon as possible after diagnosis. The median length of symptoms was 6 months (IQR 1-12) 175 
and most children presented with a combination of skin lesions (n=52;93%), lymphadenopathy 176 
(n=52;93%) and/or palatal lesions (n=23;41%) (Table 1). The median Lansky score at baseline was 177 
80% (IQR 50-90) and number of treatments given was 6 (IQR 3-6). Seventeen (30·4%) children 178 
received additional VBE treatments when they relapsed. 179 
 180 
Number of treatments 181 
Not all children survived to receive 6 courses of chemotherapy as many of them had advanced 182 
disease. Thirty-four (60·1%) children completed all 6 treatments. .  183 
 184 
HIV negative children  185 
All eight (14%) HIV-negative children presented with generalized (n=5) or localized (n=3) 186 
lymphadenopathy. Six had associated oedema, three had palatal lesions and one had a pleural 187 
effusion. Skin lesions if present were few in number. These children were younger (mean age 6·9 188 
(range 2-13 years) than HIV-infected children (mean age 7·9 (range 1-15 years). The ratio of males 189 
to females was 7:1 compared to 1·8:1 in HIV-infected children. Two of the 8 children had a sibling 190 
who had also been treated for KS. Both were diagnosed by histology and presented with generalized 191 
lymphadenopathy. Two children died during treatment, one of the five who completed treatment 192 
absconded, three had complete responses, one had a partial response and one had stable disease.  193 
 194 
Outcomes 195 
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In 18 (32%) children there was complete response to treatment; partial response (>50% reduction in 196 
size of sentinel lesion) was seen in 12 (21%), 3 (5%) were stable (<50% reduction) and 7 (12·5%) 197 
had no response or disease progression (Table 2). 198 
 199 
In 45 (80%) the quality of life, using the Lansky score pre and post treatment, was higher post 200 
therapy, 10 (18%) were unchanged and 1 (2%) deteriorated (Table 2).  201 
 202 
At 12 months; overall survival was 71% (95% CI 56-82), retention (children remaining after death 203 
and default excluded) was 60% (95% CI 45-71) and event-free survival (where event = death, 204 
default or relapse) was 50% (95% CI 36-63) (Figures 1a-c). At 24 months follow-up overall 205 
survival was 59% (95% CI 44-72) (Table 3). 206 
 207 
The risks of death and default were 26·4% (95% CI 16-39) and 13·4% (95% CI 6-24) at 12 months 208 
and 36·1% (95% CI 24-49) and 21·1% (95% CI 11-33) at 24 months respectively (Table 4). 209 
 210 
Multivariate analysis 211 
Overall, only a greater number of treatments was significantly associated with a protective effect 212 
from death, loss to follow up (LTFU) or an event, HR 0·45 (95% CI 0·30-0·69). For children 213 
completing treatment previous TB treatment was associated with an increased risk of attrition HR 214 
3·47 (95% CI 0·94-12·75). 215 
 216 
 217 
Discussion 218 
 219 
Studies have shown that a combination of ART and chemotherapy in HIV-KS leads to better 220 
outcomes than either treatment alone.19,20 Questions still remain as to what is the best chemotherapy 221 
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option for disease reduction and for quality of life. Adult studies report that triple drug regimens are 222 
better than single or dual drug regimens21-23 Few studies have adequately studied the impact of 223 
chemotherapy on KS in children or the most appropriate chemotherapy regimen, especially in 224 
resource-limited settings. To our knowledge this is the first report of the use of the combination of 225 
vincristine, bleomycin and etoposide (VBE) for children with KS.  226 
 227 
Our study shows improvement in survival of children treated for KS with VBE combination therapy 228 
at 12 months of 71% (95% CI 56-82) and 24 months 59% (95% CI 44-72), compared to the best 229 
performing therapy in the RCT study of individual therapies: oral etoposide with survival of 66% 230 
(95% CI 46-80) at 12 months and 43% (95% CI 21-63) at 24 months. However the increased risk of 231 
death in the oral etoposide group compared to our VBE combination cohort is not statistically 232 
significant on multivariate analysis HR 1·87 (95% CI 0·89-3·94) (Supplementary Table S1). Due to 233 
small numbers of children in both of these studies we do not have sufficient power to detect a 234 
significant difference at this level. 235 
 236 
Our study shows combination VBE therapy has improved complete response rates to treatment; 237 
32% compared to 9% for oral etoposide, 7% for vincristine and 17% for vincristine//bleomycin. As 238 
ART therapy significantly affects outcomes in KS, and as there was a significant difference 239 
between the duration of ART prior to starting chemotherapy between the VBE cohort and the RCT 240 
population, this could be a significant confounder, as shown by loss of significance on multivariate 241 
analysis (Supplementary Table S2). However, due to small numbers of children, we did not have 242 
the power to detect a significant difference. 243 
 244 
There was a higher proportion of children with an improved quality of life post chemotherapy in the 245 
VBE cohort  (80% v 72% with oral etoposide, the next best performing therapy (Table 2)) but this 246 
difference was not statistically significant (Supplementary Table S2). 247 
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 .  248 
It is important to consider default as well as death, as loss to follow-up can be missed deaths, and 249 
this was not accounted for in previous studies. The risk of default in the RCT was slightly lower at 250 
9·8% (95% CI 2·5-23·1) in the oral etoposide group and 10·7% (95% CI 2·7-25) in the vincristine/ 251 
bleomycin group at 12 months. This compares to 13·4 % (95% CI 5·9-24·1) in our study at 12 252 
months (Table 4). However, overall retention rates (children remaining after excluding death and 253 
default) were higher in our study 43% (95% CI 29-55) at 24 months compared to the best 254 
performing agent oral etoposide in the RCT 38% (95% CI 18-57) (Table 3). 255 
 256 
To separate the effects of chemotherapy from early mortality of very ill children who died of 257 
overwhelming disease, the children who completed the full course of treatments were analysed 258 
separately. Their survival rates were 87% at 12 months and 75% at 24 months. 259 
 260 
Increasing number of treatments was the biggest protective factor for death, attrition and any event 261 
(including relapse). This probably reflects that children with more advanced disease or lower CD4 262 
counts at baseline were likely to die early regardless of treatment. Even when the multivariate 263 
analysis was repeated without number of treatments, the main protective factor for death and any 264 
event was increasing Lansky score at baseline with marginal significance (HR 0·98 and 0·99). 265 
Supportive care that includes nutritional support, refund of travel expenses and early management 266 
of infection has remained unchanged over the last decade.  267 
 268 
In some observational studies HIV-infected children with KS were given various chemotherapies in 269 
addition to ART. Of 81 children in Botswana and Malawi, 62 received vincristine/bleomycin and 8 270 
also received doxorubicin. Twenty-three of the 36 (64%) children treated with combination 271 
chemotherapy were alive at 12 months. All 14 children treated with single-agent chemotherapy 272 
died. Of the children who achieved complete remission, 4 had received vincristine, bleomycin and 273 
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doxorubicin and 8 had received vincristine and bleomycin.10 A review of 70 children from South 274 
African hospitals reported 40% survival using single or multi-drug combinations of vincristine, 275 
doxorubicin and bleomycin in 52 children who were followed for an average of 16 months.12 A 276 
study of 28 Mozambiquan children treated with paclitaxel and followed for 27 months reported 277 
67% survival, but 4 children died of drug-related toxicity.13 In 73 Ugandan children, 23 of the 24 278 
who received chemotherapy with known outcomes had complete or partial remissions; 17 (70%) 279 
achieved complete remission; 6 achieved partial remission. No difference was observed in outcome 280 
when one or two drugs were given. However there was significant loss to follow up, numbers were 281 
small and length of follow up was not documented.11 It is difficult to compare survival outcomes in 282 
all these studies without knowing the stages of the HIV and KS infections and of any co–infections.  283 
 284 
All studies, including ours have shown that paediatric KS is more common in males than females 285 
and presents at a median age of 8 years. Reassuringly more HIV-infected children in our study were 286 
already on ART than in previous studies.  287 
 288 
There were fewer earlier deaths when using VBE combination treatment as opposed to single or 289 
dual drug treatment. Overall outcome may be similar because of the underlying HIV infection, with 290 
non-KS causes of death. Importantly, it is a palliative treatment based on quality of life . Quality of 291 
life, essential in the care of KS children, improved with treatment. Children with poor outcomes had 292 
the highest increases in Lansky score showing how important a role treatment plays in palliative 293 
care. This aspect of care has not been reported in other paediatric KS studies from the African 294 
continent. 295 
 296 
 297 
Limitations 298 
 299 
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The main limitation to this study, and other paediatric KS studies, were the small numbers. This 300 
meant that we could not adequately power our statistical analysis of the various outcomes to detect 301 
significant difference in outcomes. Some children were lost to follow-up, although loss 13·4% at 12 302 
months and of 21% at 24 months is comparable to other studies11,15 and survival estimates were 303 
adjusted for this loss. CD4 counts were incomplete. Risk stratifying patients based on clinical 304 
characteristics as proposed by El-Mallawany et al8, may improve overall outcome by guiding 305 
treatment more appropriately.   306 
 307 
We did not specifically record side-effects of treatment or specifics around cause of death. We were 308 
aware of the concerns regarding bleomycin affecting lung interstitium. No clinically significant 309 
problems were seen with bleomycin in our patients and though we investigated chest problems as 310 
fully as possible it remains difficult to say if signs and symptoms were due to KS, bleomycin or 311 
HIV itself.  It is also hard to say if some of the HIV-infected children developed KS IRIS after 312 
starting ART or it was a new infection. It would be an important consideration for future studies to 313 
record toxicity and toxic deaths related to chemotherapeutic agents. 314 
 315 
The raw data from the previous RCT study was re-analysed for direct comparison with this study 316 
and therefore outcomes vary slightly from those previously reported. 317 
 318 
Conclusion 319 
 320 
This study shows that a combination regimen of vincristine, bleomycin and etoposide for treatment 321 
of childhood KS in resource-limited settings may improve survival, response to treatment and 322 
quality of life, but numbers were inadequate to confirm significant improvement. Larger clinical 323 
trials of this and other chemotherapy options in paediatric populations would validate treatment 324 
guidance.  325 
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Legends 352 
 353 
Table 1. Baseline Characteristics of 56 children with Kaposi Sarcoma treated with vincristine, 354 
bleomycin and etoposide and 91 children treated in an open randomized study of etoposide v 355 
vincristine v bleomycin and etoposide. Statistically significant values (p<0.05) are bolded. 356 
 357 
Table 2. Treatment response and change in quality of life of children with Kaposi Sarcoma 358 
following treatment with combination therapy; vincristine, bleomycin and etoposide compared with 359 
individual therapies. 360 
 361 
Table 3. Comparison of survival, retention (children remaining after death & loss to follow-up 362 
excluded) and event-free survival (event = death, loss to follow-up or relapse) at 12 and 24 months 363 
for VBE combination therapy and individual E, V and VB therapies. 364 
 365 
Table 4. Competing risks of death and default at 12 and 24 months for VBE combination therapy 366 
and individual E, V and VB therapies.  367 
 368 
Supplementary Table S1. Hazard ratios of death, default (loss to follow-up) and event (death, loss 369 
to follow-up or relapse) using cox regression for individual drug therapies compared to combination 370 
VBE therapy.   371 
 372 
Supplementary Table S2. Odds ratios of having poor, stable or partial response to treatment (i.e. 373 
not complete response) and odds ratios of deterioration or no improvement in quality of life of study 374 
drugs in RCT study compared to VBE combination therapy using logistic regression. 375 
 376 
Figures 1A-C. Survival, retention and event-free survival for VBE combination therapy compared 377 
to separate E, V, and VB therapies over 24 months.  378 
 379 
 380 
 381 
 382 
 383 
 384 
 385 
 386 
 387 
 388 
 389 
 390 
 391 
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